Rapamycin ameliorates proteinuria and restores nephrin and podocin expression in experimental membranous nephropathy

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Stratakis, Stavros ^a   Stylianou, Kostas ^a   Petrakis, Ioannis ^a   Mavroeidi, Vasiliki ^a   Poulidaki, Rafaela ^a   Petra, Christina ^a   Moisiadis, Demitrios ^a   Stratigis, Spyros ^a   Vardaki, Eleftheria ^a   Nakopoulou, Lydia ^b   Daphnis, Eugene ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALLOANTIBODY; CREATININE; NEPHRIN; PODOCIN; PROTEIN; RAPAMYCIN; MEMBRANE PROTEIN; SIGNAL PEPTIDE;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ELECTRON MICROSCOPY; EXPERIMENTAL MODEL; GENE; GENE EXPRESSION; HEYMANN NEPHRITIS; HISTOLOGY; IMMUNOFLUORESCENCE; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHRIN GENE; NONHUMAN; PASSIVE HEYMANN NEPHRITIS; PODOCIN GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULUS; METABOLISM; PATHOLOGY; ULTRASTRUCTURE; DRUG EFFECT;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLOMERULONEPHRITIS, MEMBRANOUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY GLOMERULUS; MALE; MEMBRANE PROTEINS; PROTEINURIA; RATS; SIROLIMUS;

EID: 84884254159     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/941893     Document Type: Article

References (38)

1. Ponticelli C., Membranous nephropathy. Journal of Nephrology 2007 20 3 268 287 2-s2.0-35348888421
2. Schieppati A., Mosconi L., Perna A., Mecca G., Bertani T., Garattini S., Remuzzi G., Prognosis of untreated patients with idiopathic membranous nephropathy. The New England Journal of Medicine 1993 329 2 85 89 2-s2.0-0027314667 10.1056/NEJM199307083290203
3. Ponticelli C., Zucchelli P., Passerini P., Cesana B., Locatelli F., Pasquali S., Sasdelli M., Redaelli B., Grassi C., Pozzi C., Bizzarri D., Banfi G., A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney International 1995 48 5 1600 1604 2-s2.0-0028785260
4. Jha V., Ganguli A., Saha T. K., Kohli H. S., Sud K., Gupta K. L., Joshi K., Sakhuja V., A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. Journal of the American Society of Nephrology 2007 18 6 1899 1904 2-s2.0-34249894713 10.1681/ASN.2007020166
5. Polanco N., Gutiérrez E., Covarsí A., Ariza F., Carreño A., Vigil A., Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. Journal of the American Society of Nephrology 2010 21 4 697 704
6. Hogan S. L., Muller K. E., Jennette J. C., Falk R. J., A review of therapeutic studies of idiopathic membranous glomerulopathy. American Journal of Kidney Diseases 1995 25 6 862 875 2-s2.0-0029009350
7. Cattran D. C., Pei Y., Greenwood C. M. T., Ponticelli C., Passerini P., Honkanen E., Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney International 1997 51 3 901 907 2-s2.0-0030934029
8. Shiiki H., Saito T., Nishitani Y., Mitarai T., Yorioka N., Yoshimura A., Yokoyama H., Nishi S., Tomino Y., Kurokawa K., Sakai H., Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney International 2004 65 4 1400 1407 2-s2.0-12144287825 10.1111/j.1523-1755. 2004.00518.x
9. Beck L. H. Jr., Bonegio R. G. B., Lambeau G., Beck D. M., Powell D. W., Cummins T. D., Klein J. B., Salant D. J., M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. The New England Journal of Medicine 2009 361 1 11 21 2-s2.0-67649658244 10.1056/NEJMoa0810457
10. Debiec H., Nauta J., Coulet F., Van Der Burg M., Guigonis V., Schurmans T., De Heer E., Soubrier F., Janssen F., Ronco P., Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. The Lancet 2004 364 9441 1252 1259 2-s2.0-4744375611 10.1016/S0140-6736(04)17142-0
11. Debiec H., Lefeu F., Kemper M. J., Niaudet P., Deschênes G., Remuzzi G., Ulinski T., Ronco P., Early-childhood membranous nephropathy due to cationic bovine serum albumin. The New England Journal of Medicine 2011 364 22 2101 2110 2-s2.0-79957813444 10.1056/NEJMoa1013792
12. Prunotto M., Carnevali M. L., Candiano G., Murtas C., Bruschi M., Corradini E., Trivelli A., Magnasco A., Petretto A., Santucci L., Mattei S., Gatti R., Scolari F., Kador P., Allegri L., Ghiggeri G. M., Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. Journal of the American Society of Nephrology 2010 21 3 507 519 2-s2.0-77949902393 10.1681/ASN.2008121259
13. Ronco P., Debiec H., Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. Journal of the American Society of Nephrology 2010 21 4 564 569 2-s2.0-77950607981 10.1681/ASN. 2009121220
14. Ronco P., Debiec H., Pathogenesis of membranous nephropathy: recent advances and future challenges. Nature Reviews Nephrology 2012 8 4 203 213 2-s2.0-84859007767 10.1038/nrneph.2012.35
15. Heymann W., Hackel D. B., Harwood S., Wilson S. G., Hunter J. L., Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proceedings of the Society for Experimental Biology and Medicine 1959 100 4 660 664
16. Salant D. J., Quigg R. J., Cybulsky A. V., Heymann nephritis: mechanisms of renal injury. Kidney International 1989 35 4 976 984 2-s2.0-0024598866
17. Ruggenenti P., Cravedi P., Chianca A., Perna A., Ruggiero B., Gaspari F., Rituximab in idiopathic membranous nephropathy. Journal of the American Society of Nephrology 2012 23 8 1416 1425
18. Beck L. H. Jr., Fervenza F. C., Beck D. M., Bonegio R. G. B., Malik F. A., Erickson S. B., Cosio F. G., Cattran D. C., Salant D. J., Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. Journal of the American Society of Nephrology 2011 22 8 1543 1550 2-s2.0-79960948754 10.1681/ASN.2010111125
19. Aagaard-Tillery K. M., Jelinek D. F., Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cellular Immunology 1994 156 2 493 507 2-s2.0-0028093139 10.1006/cimm.1994.1193
20. Heidt S., Roelen D. L., Eijsink C., Van Kooten C., Claas F. H. J., Mulder A., Effects of immunosuppressive drugs on purified human b cells: evidence supporting the use of mmf and rapamycin. Transplantation 2008 86 9 1292 1300 2-s2.0-58149143166 10.1097/TP.0b013e3181874a36
21. Bonegio R. G. B., Fuhro R., Wang Z., Valeri C. R., Andry C., Salant D. J., Lieberthal W., Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. Journal of the American Society of Nephrology 2005 16 7 2063 2072 2-s2.0-27744489524 10.1681/ASN.2004030180
22. Naumovic R., Jovovic D., Basta-Jovanovic G., Miloradovic Z., Mihailovic-Stanojevic N., Aleksic T., Jovanovic D., Effects of rapamycin on active Heymann nephritis. American Journal of Nephrology 2007 27 4 379 389 2-s2.0-34447564166 10.1159/000103918
23. Deegens J. K. J., Dijkman H. B. P. M., Borm G. F., Steenbergen E. J., Van Den Berg J. G., Weening J. J., Wetzels J. F. M., Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney International 2008 74 12 1568 1576 2-s2.0-57049180117 10.1038/ki.2008.413
24. Rovira J., Arellano E. M., Carreras J., Campos B., Vodenik B., Bañón-Maneus E., Ramírez-Bajo M. J., Moya-Rull D., Solé-González A., Hernández A., Revuelta I., Quintana L. F., Howat W. J., Campistol J. M., Diekmann F., Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction. Transplantation 2009 88 5 646 652 2-s2.0-70349568501 10.1097/TP.0b013e3181b24463
25. Wu M.-J., Wen M.-C., Chiu Y.-T., Chiou Y.-Y., Shu K.-H., Tang M.-J., Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney International 2006 69 11 2029 2036 2-s2.0-33745269545 10.1038/sj.ki.5000161
26. Lloberas N., Cruzado J. M., Franquesa M., Herrero-Fresneda I., Torras J., Alperovich G., Rama I., Vidal A., Grinyó J. M., Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. Journal of the American Society of Nephrology 2006 17 5 1395 1404 2-s2.0-33646352217 10.1681/ASN.2005050549
27. Lui S. L., Yung S., Tsang R., Zhang F., Chan K. W., Tam S., Chan T. M., Rapamycin prevents the development of nephritis in lupus-prone NZB/W F 1 mice. Lupus 2008 17 4 305 313 2-s2.0-43249109614 10.1177/0961203307088289
28. Lui S. L., Tsang R., Chan K. W., Zhang F., Tam S., Yung S., Chan T. M., Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. Nephrology Dialysis Transplantation 2008 23 9 2768 2776 2-s2.0-58549107810 10.1093/ndt/gfn216
29. Stylianou K., Petrakis I., Mavroeidi V., Stratakis S., Vardaki E., Perakis K., Stratigis S., Passam A., Papadogiorgaki E., Giannakakis K., Nakopoulou L., Daphnis E., The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. Nephrology Dialysis Transplantation 2011 26 2 498 508 2-s2.0-79551471312 10.1093/ndt/gfq496
30. Krämer S., Wang-Rosenke Y., Scholl V., Binder E., Loof T., Khadzhynov D., Kawachi H., Shimizu F., Diekmann F., Budde K., Neumayer H.-H., Peters H., Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. American Journal of Physiology 2008 294 2 F440 F449 2-s2.0-38849201733 10.1152/ajprenal.00379.2007
31. Wittmann S., Daniel C., Braun A., Vogelbacher R., Shimizu F., Kawachi H., Hugo C., The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat. Nephron 2008 108 2 e45 e56 2-s2.0-40449083541 10.1159/000116112
32. Vogelbacher R., Wittmann S., Braun A., Daniel C., Hugo C., The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007 84 11 1492 1499 2-s2.0-37349107870 10.1097/01.tp.0000282866.92367.99
33. Daniel C., Ziswiler R., Frey B., Pfister M., Marti H.-P., Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Experimental Nephrology 2000 8 1 52 62 2-s2.0-0033984112
34. Daniel C., Renders L., Amann K., Schulze-Lohoff E., Hauser I. A., Hugo C., Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. American Journal of Transplantation 2005 5 12 2849 2861 2-s2.0-33644825821 10.1111/j.1600-6143.2005.01120.x
35. Fervenza F. C., Fitzpatrick P. M., Mertz J., Erickson S. B., Liggett S., Popham S., Wochos D. N., Synhavsky A., Hippler S., Larson T. S., Bagniewski S. M., Velosa J. A., Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrology Dialysis Transplantation 2004 19 5 1288 1292 2-s2.0-2442442944 10.1093/ndt/gfh079
36. Stylianou K., Petrakis I., Mavroeidi V., Stratakis S., Kokologiannakis G., Lioudaki E., Rapamycin induced ultrastructural and molecular alterations in glomerular podocytes in healthy mice. Nephrology Dialysis Transplantation 2012 27 8 3141 3148
37. Torras J., Herrero-Fresneda I., Gulias O., Flaquer M., Vidal A., Cruzado J. M., Lloberas N., Franquesa M., Grinyó J. M., Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage. Nephrology Dialysis Transplantation 2009 24 12 3632 3640 2-s2.0-71049162614 10.1093/ndt/gfp367
38. Battaglia M., Stabilini A., Migliavacca B., Horejs-Hoeck J., Kaupper T., Roncarolo M.-G., Rapamycin promotes expansion of functional CD4+CD25 +FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. Journal of Immunology 2006 177 12 8338 8347 2-s2.0-33845379986